OpGen Raises Total of $20M in Series B Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.